Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Talimogene laherparepvec
Synonyms
Therapy Description

Imlygic (talimogene laherparepvec) is a GM-CSF expressing herpes simplex type-1 virus (HSV-1) that selectively infects and lyses tumor cells, and potentially induces a cytotoxic immune response against tumor cells (PMID: 25777572). Imlygic (talimogene laherparepvec) is FDA approved for use in patients with recurrent melanoma (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Talimogene laherparepvec Imlygic OncoVEX GM-CSF|T-VEC Imlygic (talimogene laherparepvec) is a GM-CSF expressing herpes simplex type-1 virus (HSV-1) that selectively infects and lyses tumor cells, and potentially induces a cytotoxic immune response against tumor cells (PMID: 25777572). Imlygic (talimogene laherparepvec) is FDA approved for use in patients with recurrent melanoma (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02658812 Phase II Talimogene laherparepvec Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery Terminated USA 0
NCT03086642 Phase I Talimogene laherparepvec Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer Active, not recruiting USA 0
NCT04427306 Phase II Talimogene laherparepvec Neoadjuvant T-VEC in High Risk Early Melanoma Recruiting USA 0
NCT02756845 Phase I Talimogene laherparepvec Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors Active, not recruiting USA | ITA | FRA | ESP | CAN | BEL 1
NCT01740297 Phase Ib/II Ipilimumab Talimogene laherparepvec Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma Completed USA | FRA | DEU 0
NCT02819843 Phase II Talimogene laherparepvec A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors Active, not recruiting USA 0
NCT03663712 Phase I Talimogene laherparepvec Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO) Completed USA 0
NCT04599062 Phase Ib/II Talimogene laherparepvec TVEC and Preop Radiation for Sarcoma (8 ml Dose) Recruiting USA 0
NCT02263508 Phase Ib/II Pembrolizumab Talimogene laherparepvec MK-3475 With or Without Talimogene Laherparepvec in Unresected Melanoma Terminated USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 13
NCT04065152 Phase II Talimogene laherparepvec Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma (KAPVEC) Recruiting FRA 0
NCT02453191 Phase Ib/II Talimogene laherparepvec TVEC and Preop Radiation for Sarcoma Active, not recruiting USA 0
NCT02509507 Phase I Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab Active, not recruiting USA | ESP | DEU | BEL | AUT 4
NCT02923778 Phase II Talimogene laherparepvec Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Recruiting USA | CAN 0


Additional content available in CKB BOOST